Related Experiment Video
Updated: Jan 29, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
Genomic Enrichment and Functional Impact of TP53 and CYLD Alterations in Recurrent and Metastatic HPV-Associated Head
Manu Prasad1,2, Alex T Cheng1,2,3, Marcel Mayer1,2,4
1Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Purpose:
Recurrent and metastatic human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (R/M HPV+ HNSCC) remains largely incurable, with genetic drivers incompletely defined. We profiled the genetic landscape of R/M HPV+ HNSCC and functionally characterized genetic alterations strongly enriched in this cancer type.
Experimental Design:
We identified genetic alterations uniquely enriched in 159 R/M HPV+ tumors. High-priority alterations were functionally modeled, examining proliferation, clonogenicity, migration/invasion, apoptosis, therapy response, in vivo growth, metastasis, and immune contexture.
Results:
Compared with HPV+ primary tumors, R/M HPV+ tumors were enriched for TP53 mutations (prespecified FDR threshold met; OR, 6.23; P = 0.02) and were associated with poorer survival. Within R/M disease, cylindromatosis lysine 63 deubiquitinase (CYLD) alterations were specific to HPV+ tumors (21% vs. 0% in HPV-). TP53 mutations were predominantly clonal and associated with whole-genome duplication. Expression of TP53 gain-of-function (GOF) mutants (R175H, G245C, R273C) in HPV+ HNSCC cells increased clonogenic survival, migration/invasion, lung metastatic burden in vivo, and cisplatin IC50, without altering radiation sensitivity. CYLD knockdown accelerated cellular growth yet increased radiosensitivity. Transcriptomic analyses linked CYLD loss to NF-κB/TNFα pathway activation, a T cell-inflamed microenvironment, and checkpoint upregulation.
Conclusions:
R/M HPV+ HNSCC is genomically and functionally shaped by two axes with therapeutic implications: TP53 GOF mutations promote metastatic phenotypes and cisplatin resistance, whereas CYLD loss defines an HPV-specific subset with enhanced radiation sensitivity and immune activation. These data support using TP53 and CYLD as predictive biomarkers to guide investigation into precision strategies for systemic therapy choices, p53-targeted/Wee1 strategies, and radiotherapy-immunotherapy combinations in high-risk or R/M HPV+ HNSCC.
Insights
Recurrent, metastatic HPV-associated head and neck cancer is driven by TP53 mutations promoting metastasis and cisplatin resistance. CYLD loss in HPV+ tumors enhances radiation sensitivity and immune activation, suggesting biomarker potential.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Recurrent and metastatic human papillomavirus-associated head and neck squamous cell carcinoma (R/M HPV+ HNSCC) presents a significant clinical challenge with limited curative options.
- The underlying genetic drivers of R/M HPV+ HNSCC are not fully understood, hindering the development of targeted therapies.
Purpose of the Study:
- To profile the genetic landscape of R/M HPV+ HNSCC.
- To functionally characterize genetic alterations enriched in this cancer type.
Main Methods:
- Comparative genomic profiling of 159 R/M HPV+ tumors against primary tumors.
- Functional modeling of high-priority genetic alterations (TP53, CYLD) assessing cellular phenotypes, in vivo growth, metastasis, and therapy response.
- Transcriptomic analysis to elucidate downstream molecular pathways and immune microenvironment.
Main Results:
- TP53 mutations were significantly enriched in R/M HPV+ tumors compared to primary HPV+ tumors, correlating with poorer survival.
- CYLD alterations were specific to HPV+ HNSCC, not observed in HPV- tumors.
- TP53 gain-of-function mutants promoted metastatic potential and cisplatin resistance, while CYLD loss enhanced radiosensitivity and T-cell-inflamed microenvironment signatures.
Conclusions:
- R/M HPV+ HNSCC progression is influenced by TP53 gain-of-function mutations and CYLD loss.
- TP53 mutations confer metastatic phenotypes and cisplatin resistance.
- CYLD loss identifies a subset of HPV+ HNSCC with increased radiosensitivity and immune activation, suggesting potential for combination therapies.
More Related Videos
Related Concept Videos
Arteries of the Head and Neck
The internal carotid arteries supply blood to the anterior portion of the cerebrum. They enter the...
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
Genomics
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Altered States of Awareness
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
Muscles of the Anterior Neck

